SurModics (SRDX) Tops Q1 EPS by 10c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Surmodics Reports First Quarter Fiscal 2017 Results
February 2, 2017 7:30 AM ESTGAAP Revenue of $17.8 Million, up 7%; Medical Device increase 12% GAAP EPS of $0.17, Non-GAAP EPS of $0.19 Raises Revenue and EPS Guidance
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 first quarter, ended December 31, 2016.
The Surmodics team made meaningful investments in our whole-product strategy while delivering top-line growth in the first quarter of fiscal... More
